Roche and Iceland Genomics sign cancer biomarker agreement
Iceland Genomics (IGC), a privately held cancer biology company, and Roche Diagnostics, of Basel, Switzerland, have entered into a cancer biomarker discovery collaboration.
Iceland Genomics (IGC), a privately held cancer biology company, and Roche Diagnostics, of Basel, Switzerland, have entered into a cancer biomarker discovery collaboration.
The two companies will jointly analyse patient samples to validate novel molecular markers for diagnostic tests in order to predict recurrence of cancer for selected tumor entities.
The agreement will provide IGC with access to certain gene expression data and support for further biological characterisation of the patient samples in Iceland. Financial terms were not disclosed.